SearcharxivSearch

arXiv subjects

Kathy Li

Publications and source records attributed to Kathy Li.

3 recordsLinked to original sources

A generative, predictive model for menstrual cycle lengths that accounts for potential self-tracking artifacts in mobile health data

Mobile health (mHealth) apps such as menstrual trackers provide a rich source of self-tracked health observations that can be leveraged for health-relevant research. However, such data streams have questionable reliability since they hinge on user adherence to the app. Therefore, it is crucial for researchers to separate true behavior from self-tracking artifacts. By taking a machine learning approach to modeling self-tracked cycle lengths, we can both make more informed predictions and learn the underlying structure of the observed data. In this work, we propose and evaluate a hierarchical, generative model for predicting next cycle length based on previously-tracked cycle lengths that accounts explicitly for the possibility of users skipping tracking their period. Our model offers several advantages: 1) accounting explicitly for self-tracking artifacts yields better prediction accuracy as likelihood of skipping increases; 2) because it is a generative model, predictions can be updated online as a given cycle evolves, and we can gain interpretable insight into how these predictions change over time; and 3) its hierarchical nature enables modeling of an individual's cycle length history while incorporating population-level information. Our experiments using mHealth cycle length data encompassing over 186,000 menstruators with over 2 million natural menstrual cycles show that our method yields state-of-the-art performance against neural network-based and summary statistic-based baselines, while providing insights on disentangling menstrual patterns from self-tracking artifacts. This work can benefit users, mHealth app developers, and researchers in better understanding cycle patterns and user adherence.

cs.LG

Characterizing physiological and symptomatic variation in menstrual cycles using self-tracked mobile health data

The menstrual cycle is a key indicator of overall health for women of reproductive age. Previously, menstruation was primarily studied through survey results; however, as menstrual tracking mobile apps become more widely adopted, they provide an increasingly large, content-rich source of menstrual health experiences and behaviors over time. By exploring a database of user-tracked observations from the Clue app by BioWink of over 378,000 users and 4.9 million natural cycles, we show that self-reported menstrual tracker data can reveal statistically significant relationships between per-person cycle length variability and self-reported qualitative symptoms. A concern for self-tracked data is that they reflect not only physiological behaviors, but also the engagement dynamics of app users. To mitigate such potential artifacts, we develop a procedure to exclude cycles lacking user engagement, thereby allowing us to better distinguish true menstrual patterns from tracking anomalies. We uncover that women located at different ends of the menstrual variability spectrum, based on the consistency of their cycle length statistics, exhibit statistically significant differences in their cycle characteristics and symptom tracking patterns. We also find that cycle and period length statistics are stationary over the app usage timeline across the variability spectrum. The symptoms that we identify as showing statistically significant association with timing data can be useful to clinicians and users for predicting cycle variability from symptoms or as potential health indicators for conditions like endometriosis. Our findings showcase the potential of longitudinal, high-resolution self-tracked data to improve understanding of menstruation and women's health as a whole.

q-bio.QM

Dose-response modeling in high-throughput cancer drug screenings: An end-to-end approach

Personalized cancer treatments based on the molecular profile of a patient's tumor are an emerging and exciting class of treatments in oncology. As genomic tumor profiling is becoming more common, targeted treatments to specific molecular alterations are gaining traction. To discover new potential therapeutics that may apply to broad classes of tumors matching some molecular pattern, experimentalists and pharmacologists rely on high-throughput, in-vitro screens of many compounds against many different cell lines. We propose a hierarchical Bayesian model of how cancer cell lines respond to drugs in these experiments and develop a method for fitting the model to real-world high-throughput screening data. Through a case study, the model is shown to capture nontrivial associations between molecular features and drug response, such as requiring both wild type TP53 and overexpression of MDM2 to be sensitive to Nutlin-3(a). In quantitative benchmarks, the model outperforms a standard approach in biology, with ~20% lower predictive error on held out data. When combined with a conditional randomization testing procedure, the model discovers biomarkers of therapeutic response that recapitulate known biology and suggest new avenues for investigation. All code for the paper is publicly available at https://github.com/tansey/deep-dose-response.

stat.AP